Search
Close this search box.
    • Small Molecules
      • Discovery
    • Biologics
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery
      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

    • Industries
    • Emerging Biopharma
      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

    • Dedicated Centers
      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

    • Center for Advanced Protein Studies (CAPS)
      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

  • Careers
Search
Close this search box.

iPSC Platform

iPSC Platform

High-quality iPSC products and services for accelerated drug discovery

Induced pluripotent stem cells (iPSC)-based disease modelling has revolutionized the ways in which we explore the mechanisms of human diseases and develop therapies. While iPSCs offer an attractive and robust in vitro disease model for novel drug development, their genetic instability, heterogeneity, and quality control remain a matter of concern. At Syngene, we have successfully generated high quality iPSCs followed by extensive characterization to ensure quality of the final clones and their derivatives. 

With our experience and expertise in this area, we provide solutions to generate feeder free and viral integration free iPSC clones meant for cellular assays and screening. We perform iPSC reprogramming, characterization, gene editing using CRISPR and advanced nucleases, differentiation of iPSCs into multiple lineages and in vitro assays using iPSC derivatives or primary cells. We also have expertise in CAR-T platform. To know more, click here.

Our iPSC product offerings

  • iPSC reprogramming – Integration free (Sendai, episomal); feeder free from healthy or diseased patients
  • Guaranteed high reprogramming efficiency
  • Well established SOPs to generate high quality iPSCs; experience in generating CAR-T, neuronal and cardiomyocyte lines
  • Extensive QC and CoA preparation for every batch to produce consistent results
  • Carefully monitored LN2 storage to ensure >80% cell viability upon thawing
  • Tie-ups with local hospitals for availability of diverse starting material for iPSC reprogramming
  • Well established donor network, including sample collection procedure
  • Extensive screening processes for each donor sample to ensure high sample quality
  • Availability of automated cell banking for systematic storage of donor samples

Syngene’s iPSC product range

Representative phase contrast images and molecular characterization by immunocytochemistry (ICC) for pluripotency check of iPSC lines developed at Syngene

We offer different levels of services ranging from custom iPSCs generation to gene editing and differentiation of iPSCs into multiple lineages to help you with disease-specific cell models, developing precision medicines and for accelerating your research.

Steps for generating and delivering custom iPSCs

Gene Editing

Using CRISPR licensed technology we provide gene editing services in iPSC cells that involves gene knock-out and knock-in for disease modelling, allogenic therapies, and reporter cell line generation for drug screening.

Our Gene editing platforms

  • Autologous and allogenic cell lines for disease modelling and drug screening
  • Cas9 based genome editing
  • Lentivirus/AAV-based gene editing
  • Expertise in gene/base editing
  • Single cell biallelic KO clones- monoclones/bulk-pool
  • Tagged reporter cell lines for drug screening
  • CAR-T, TCR-T modulation of immune cells

CRISPR capabilities

Our CRISPR package includes gRNA designing, KO generation, validation, and assays. We have extensive experience in multiple gene knock-outs in iPSCs and generating allogenic CAR-iPSCs for CAR-T cell therapy. Representative data of creating double KO with >90% efficiency using Cas9 in iPSC cell line is shown below:

Knock out generation using CRISPR Cas9 in several iPSCs and primary cells.

Differentiation of iPSCs into multiple cell lineages

We offer services for differentiation of iPSCs into multiple cell lineages including cardiomyocytes, neural stem cells, Neurons, astrocytes, hematopoietic stem cells, T cells etc. 

iPSC assays

Our assay development team offers a broad range of in vitro assays on iPSCs and primary cells.

  • Cell-based assays
  • Immune assays
  • Drug screening
  • 3D spheroids
  • Disease modeling

Our range of iPSC-derived cell-based assays

Syngene’s iPSC-derived cell-based and immune assays and their readouts

Drug screening

  • Drug screening in high throughput format (96/384 well format)
  • All assays validated using established quality checks (plate uniformity, reproducibility, signal:noise ratio, Z’ prime)
  • Deliverables in the format of ready-to-present/publish
  • In-house cell repository available for screening purposes
  • Automated liquid handing/pipette stations available for reproducible results

Disease modeling

  • iPSC generation from specific disease donors and redifferentiating into desired cell lineage for research purpose or screening of novel drugs
  • iPSC generation from healthy donor and introducing distinct mutation to model a particular disease
  • Induce the iPSCs derived from healthy donors using specific media stimulation or exogenous stimulus to mimic the disease state

Your browser does not support this function.

To download, Please share your details

This Website uses Cookies

We use cookies to improve your experience on our site and show you information relevant to your requirements. To find out more, read our Privacy Policy and Cookies Policy.

To view or email, Please share your details view

To download, Please share your details